Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells

Biochemical Pharmacology

Volumn 61, Issue 7, 2001, Pages 857-865

  Zhao, Rongbao ^a   Gao, Feng ^a   Goldman, I David ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antifolate; Drug resistance; Folate cofactors; Polyglutamation

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; DIHYDROFOLATE REDUCTASE; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; LOMETREXOL; METHOTREXATE; N [5 [2 (2 AMINO 1,4,5,6,7,8 HEXAHYDRO 4 OXOPYRIDO[2,3 D]PYRIMIDIN 6 YL)ETHYL] 2 THENOYL]GLUTAMIC ACID; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE; PEMETREXED; PLEVITREXED; RALTITREXED; TRIMETREXATE;

ANIMAL CELL; ARTICLE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG COMPETITION; DRUG EXPOSURE; DRUG SENSITIVITY; ENZYME INHIBITION; IC 50; LEUKEMIA L 1210; NONHUMAN; PRIORITY JOURNAL; RODENT;

ANIMALS; BIOLOGICAL TRANSPORT; CELL DIVISION; FOLIC ACID; FOLIC ACID ANTAGONISTS; LEUCOVORIN; LEUKEMIA L1210; MICE; POLYGLUTAMIC ACID; TUMOR CELLS, CULTURED;

EID: 0035313188     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00532-9     Document Type: Article

References (41)

1. Mechanism of action of methotrexate. IV. Free intracellular methotrexate required to suppress dihydrofolate reduction to tetrahydrofolate by Ehrlich ascites tumor cells in vitro
2. Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines
3. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
4. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study
5. Augmentation of the therapeutic activity of lometrexol [(6-R)5,10-dideazatetrahydrofolate] by oral folic acid
6. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514
7. Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate
8. Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells
9. Relationships between carrier-mediated transport of folate compounds by L1210 leukemia cells: Evidence for multiplicity of entry routes with different kinetic properties expressed in plasma membrane vesicles
10. A reduced carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate
11. Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier
12. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier
13. The mechanism of transport of the multitargeted antifolate, MTA-LY231514, and its cross resistance pattern in cells with impaired transport of methotrexate
14. Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells
15. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport
16. The effect of folic acid fortification on plasma folate and total homocysteine concentrations
17. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism
18. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs
19. Biochemical pharmacology of the lipophilic antifolate, trimetrexate
20. Polyglutamation of methotrexate. Is methotrexate a prodrug?
21. δ- hemiphthaloyl-l-ornithine (PT523)
22. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase
23. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase
24. The 6S- and 6R-diastereomers of 5,10-dideaza-5,6,7,8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis
25. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase
26. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol
27. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: Correlates of molecular-structure and biological activity
28. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis
29. Mammalian folylpoly-γ-glutamate synthetase. 4. In vitro and in vivo metabolism of folates and analogues and regulation of folate homeostasis
30. Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates
31. Studies with a mathematical model of folate metabolism
32. Reversal of methotrexate binding to dihydrofolate reductase by dihydrofolate. Studies with pure enzyme and computer modeling using network thermodynamics
33. Cellular folates prevent polyglutamation of 5,10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites
34. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: Role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration
35. Phase I study of (6R)-5,10-dideazatetrahydrofolate: A folate antimetabolite inhibitory to de novo purine synthesis
36. Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: Effect of low-folate diet
37. Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts
38. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement
39. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid
40. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation
41. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue